Irritable Bowel Syndrome (IBS): Global Market Spotlight 2018 - Linzess is Forecasted to Have the Highest Revenues Until 2022 - ResearchAndMarkets.com

DUBLIN--()--The "Market Spotlight: Irritable Bowel Syndrome (IBS)" report has been added to ResearchAndMarkets.com's offering.

This report covers the irritable bowel syndrome (IBS) market, comprising key pipeline and marketed drugs, clinical trials, upcoming regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • It is estimated that in 2016, there were approximately 754 million prevalent cases of IBS in those aged 15 years and over worldwide, and forecasts that number to increase to 830 million prevalent cases by 2025.
  • The approved drugs in the IBS space target chloride channel 2, calcium channel, serotonin 5-HT3 receptor, guanylyl cyclase C receptor, opioid receptor, and RNA polymerase. These drugs are administered via the oral route.
  • Half of all industry-sponsored drugs in active clinical development for IBS are in Phase II, with just two drugs in Phase III. Therapies in mid- and late-stage development for IBS focus on a wide variety of targets. The majority of the pipeline drugs for IBS are administered via the oral route, while dalazatide and PPC-5650 are subcutaneous and rectal formulations, respectively.
  • There have been 16 licensing and asset acquisition activities involving IBS drugs during 2013-18. The largest deal was the $2,905m research, development, collaboration, and license agreement in January 2017 between Allergan and Assembly Biosciences for the worldwide rights to Assembly's microbiome gastrointestinal development programs.
  • Lotronex's method of use patent and Solabegron's US parent product patent are set to expire in 2018 and 2019, respectively, which will open the door to generic entry.
  • Xifaxan's sales ranked highest during 2012-16, although the majority of its sales were for indications other than IBS. However, during 2017-22, Linzess is forecasted to have the highest revenues.
  • The distribution of clinical trials across Phases I-IV indicates that the majority of trials for IBS are in the early and mid-phases of development, with 65% of trials in Phase I-II, and only 35% in Phase III-IV.
  • The US has a substantial lead in the number of IBS clinical trials globally. The UK leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the IBS space is dominated by completed trials. GlaxoSmithKline has the highest number of completed clinical trials for IBS with 36 trials, while Allergan has the highest number of trials overall.
  • Allergan leads industry sponsors with the highest number of Phase III clinical trials for IBS, followed by Novartis and Mallinckrodt.

Key Topics Covered

  1. Overview
  2. Key Takeaways
  3. Disease Background
  4. Treatment
  5. Epidemiology
  6. Marketed Drugs
  7. Pipeline Drugs
  8. Key Regulatory Events
  9. Licensing and Asset Acquisition Deals
  10. Parent Patents
  11. Revenue Opportunity
  12. Clinical Trial Landscape

For more information about this report visit https://www.researchandmarkets.com/research/7n496l/irritable_bowel?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastrointestinal Drugs , Gastroenterology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Gastrointestinal Drugs , Gastroenterology